BRIEF—Jinghua Pharma drops development of two MAbs

Nantong, China-based Jinghua Pharmaceutical has called off the research and development of an anti-VEGFR2 monoclonal antibody (MAb) and an anti-PDL1 MAb that had been licensed from the American biotech Kadmon for the Greater China region back in 2015.

According to a statement from the company, pre-clinical trial results of the two MAbs showed little promise.

Jinghua paid Kadmon an upfront licensing fee about $3.59 million, but will not be liable to pay the potential $40 million on the achievement of milestones and 10% royalties over future sales as was agreed under the original licensing deal.